A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome

Je Hwan Lee, Jun Ho Jang, Jinny Park, Seonyang Park, Young Don Joo, Yeo Kyeoung Kim, Hoon Gu Kim, Chul Won Choi, Sung Hyun Kim, Seong Kyu Park, Eunkyung Park, Yoo Hong Min

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background Decitabine was evaluated for its efficacy and safety in Korean patients with myelodysplastic syndrome with IPSS score of 0.5 or over. Design and Methods Decitabine 20 mg/m 2/day was given intravenously over one hour for five consecutive days every four weeks. The primary end point was overall response rate. Results A total of 101 patients were analyzed. The International Prognostic Scoring System risk category was Intermediate-2/High in 47.5%. A median of 5 courses (range 1-18) were delivered. The overall response rate was 55.4% (13 complete responses, one partial response, 23 marrow complete responses, and 19 hematologic improvements). Forty-eight patients (47.5%) showed some hematologic improvement. With a median follow-up duration of 478 days (range 69- 595), median overall survival was 17.7 months. Patients who showed hematologic improvement had significantly longer overall survival than those who did not (19.2 vs. 15.9 months, P=0.006 by landmark analysis at six months). The difference in overall survival was evident in the Intermediate-2/High risk group but not in the Intermediate-1 risk group. The progressionfree survival and acute myeloid leukemia-free survival were 61.9% and 77.9% at one year, respectively. Among 489 assessable treatment courses, there were 97 fever episodes requiring intravenous antimicrobials. Conclusions Decitabine treatment was feasible and effective in Korean patients with myelodysplastic syndrome, and the overall survival was significantly longer in patients showing hematologic improvement. (ClinicalTrials.gov Identifier: NCT01041846)

Original languageEnglish
Pages (from-to)1441-1447
Number of pages7
JournalHaematologica
Volume96
Issue number10
DOIs
Publication statusPublished - 2011 Oct 1

Fingerprint

decitabine
Myelodysplastic Syndromes
Multicenter Studies
Observational Studies
Survival
Therapeutics
Acute Myeloid Leukemia
Fever
Bone Marrow

Keywords

  • Decitabine
  • MDS
  • Observational study

ASJC Scopus subject areas

  • Hematology

Cite this

A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome. / Lee, Je Hwan; Jang, Jun Ho; Park, Jinny; Park, Seonyang; Joo, Young Don; Kim, Yeo Kyeoung; Kim, Hoon Gu; Choi, Chul Won; Kim, Sung Hyun; Park, Seong Kyu; Park, Eunkyung; Min, Yoo Hong.

In: Haematologica, Vol. 96, No. 10, 01.10.2011, p. 1441-1447.

Research output: Contribution to journalArticle

Lee, JH, Jang, JH, Park, J, Park, S, Joo, YD, Kim, YK, Kim, HG, Choi, CW, Kim, SH, Park, SK, Park, E & Min, YH 2011, 'A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome', Haematologica, vol. 96, no. 10, pp. 1441-1447. https://doi.org/10.3324/haematol.2011.046078
Lee, Je Hwan ; Jang, Jun Ho ; Park, Jinny ; Park, Seonyang ; Joo, Young Don ; Kim, Yeo Kyeoung ; Kim, Hoon Gu ; Choi, Chul Won ; Kim, Sung Hyun ; Park, Seong Kyu ; Park, Eunkyung ; Min, Yoo Hong. / A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome. In: Haematologica. 2011 ; Vol. 96, No. 10. pp. 1441-1447.
@article{4a2f76f36f7345e1953f1628c6a643f6,
title = "A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome",
abstract = "Background Decitabine was evaluated for its efficacy and safety in Korean patients with myelodysplastic syndrome with IPSS score of 0.5 or over. Design and Methods Decitabine 20 mg/m 2/day was given intravenously over one hour for five consecutive days every four weeks. The primary end point was overall response rate. Results A total of 101 patients were analyzed. The International Prognostic Scoring System risk category was Intermediate-2/High in 47.5{\%}. A median of 5 courses (range 1-18) were delivered. The overall response rate was 55.4{\%} (13 complete responses, one partial response, 23 marrow complete responses, and 19 hematologic improvements). Forty-eight patients (47.5{\%}) showed some hematologic improvement. With a median follow-up duration of 478 days (range 69- 595), median overall survival was 17.7 months. Patients who showed hematologic improvement had significantly longer overall survival than those who did not (19.2 vs. 15.9 months, P=0.006 by landmark analysis at six months). The difference in overall survival was evident in the Intermediate-2/High risk group but not in the Intermediate-1 risk group. The progressionfree survival and acute myeloid leukemia-free survival were 61.9{\%} and 77.9{\%} at one year, respectively. Among 489 assessable treatment courses, there were 97 fever episodes requiring intravenous antimicrobials. Conclusions Decitabine treatment was feasible and effective in Korean patients with myelodysplastic syndrome, and the overall survival was significantly longer in patients showing hematologic improvement. (ClinicalTrials.gov Identifier: NCT01041846)",
keywords = "Decitabine, MDS, Observational study",
author = "Lee, {Je Hwan} and Jang, {Jun Ho} and Jinny Park and Seonyang Park and Joo, {Young Don} and Kim, {Yeo Kyeoung} and Kim, {Hoon Gu} and Choi, {Chul Won} and Kim, {Sung Hyun} and Park, {Seong Kyu} and Eunkyung Park and Min, {Yoo Hong}",
year = "2011",
month = "10",
day = "1",
doi = "10.3324/haematol.2011.046078",
language = "English",
volume = "96",
pages = "1441--1447",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "10",

}

TY - JOUR

T1 - A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome

AU - Lee, Je Hwan

AU - Jang, Jun Ho

AU - Park, Jinny

AU - Park, Seonyang

AU - Joo, Young Don

AU - Kim, Yeo Kyeoung

AU - Kim, Hoon Gu

AU - Choi, Chul Won

AU - Kim, Sung Hyun

AU - Park, Seong Kyu

AU - Park, Eunkyung

AU - Min, Yoo Hong

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Background Decitabine was evaluated for its efficacy and safety in Korean patients with myelodysplastic syndrome with IPSS score of 0.5 or over. Design and Methods Decitabine 20 mg/m 2/day was given intravenously over one hour for five consecutive days every four weeks. The primary end point was overall response rate. Results A total of 101 patients were analyzed. The International Prognostic Scoring System risk category was Intermediate-2/High in 47.5%. A median of 5 courses (range 1-18) were delivered. The overall response rate was 55.4% (13 complete responses, one partial response, 23 marrow complete responses, and 19 hematologic improvements). Forty-eight patients (47.5%) showed some hematologic improvement. With a median follow-up duration of 478 days (range 69- 595), median overall survival was 17.7 months. Patients who showed hematologic improvement had significantly longer overall survival than those who did not (19.2 vs. 15.9 months, P=0.006 by landmark analysis at six months). The difference in overall survival was evident in the Intermediate-2/High risk group but not in the Intermediate-1 risk group. The progressionfree survival and acute myeloid leukemia-free survival were 61.9% and 77.9% at one year, respectively. Among 489 assessable treatment courses, there were 97 fever episodes requiring intravenous antimicrobials. Conclusions Decitabine treatment was feasible and effective in Korean patients with myelodysplastic syndrome, and the overall survival was significantly longer in patients showing hematologic improvement. (ClinicalTrials.gov Identifier: NCT01041846)

AB - Background Decitabine was evaluated for its efficacy and safety in Korean patients with myelodysplastic syndrome with IPSS score of 0.5 or over. Design and Methods Decitabine 20 mg/m 2/day was given intravenously over one hour for five consecutive days every four weeks. The primary end point was overall response rate. Results A total of 101 patients were analyzed. The International Prognostic Scoring System risk category was Intermediate-2/High in 47.5%. A median of 5 courses (range 1-18) were delivered. The overall response rate was 55.4% (13 complete responses, one partial response, 23 marrow complete responses, and 19 hematologic improvements). Forty-eight patients (47.5%) showed some hematologic improvement. With a median follow-up duration of 478 days (range 69- 595), median overall survival was 17.7 months. Patients who showed hematologic improvement had significantly longer overall survival than those who did not (19.2 vs. 15.9 months, P=0.006 by landmark analysis at six months). The difference in overall survival was evident in the Intermediate-2/High risk group but not in the Intermediate-1 risk group. The progressionfree survival and acute myeloid leukemia-free survival were 61.9% and 77.9% at one year, respectively. Among 489 assessable treatment courses, there were 97 fever episodes requiring intravenous antimicrobials. Conclusions Decitabine treatment was feasible and effective in Korean patients with myelodysplastic syndrome, and the overall survival was significantly longer in patients showing hematologic improvement. (ClinicalTrials.gov Identifier: NCT01041846)

KW - Decitabine

KW - MDS

KW - Observational study

UR - http://www.scopus.com/inward/record.url?scp=80053622261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053622261&partnerID=8YFLogxK

U2 - 10.3324/haematol.2011.046078

DO - 10.3324/haematol.2011.046078

M3 - Article

C2 - 21659363

AN - SCOPUS:80053622261

VL - 96

SP - 1441

EP - 1447

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 10

ER -